By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: A Silent Disease Becoming a Public Health Emergency Metabolic
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Knowing When To Treat – AI for Transformation, Infection Risk, and
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Early detection and personalised treatment in chronic lymphocytic leukaemia (CLL) remain
Artificial intelligence continues to redefine clinical development yet much of the conversation remains driven by hype rather than hard evidence.
Volv Global continues to shape the future of AI in healthcare. This November, at Frontiers Health 2025 in Berlin, CEO
By Léon Van Wouwe, Clinical Innovation Director, Volv Global A Hidden Cancer in Plain Sight Multiple myeloma (MM) has
Léon van Wouwe, Clinical Innovation Director, Volv Global Since Volv Global first started attending the World Orphan Drug Congress, we
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: The Urgency of Early Diagnosis in Type 1 Diabetes
Introduction Artificial intelligence continues to push healthcare into a new era from early disease detection to large-scale data modelling. Yet
How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: A case study in alpha-1 antitrypsin deficiency
Volv Global at WODC Europe 2025 – Where Technology Meets Human Volv Global sits at the crucial intersection between technology
Volv Global CEO and Founder Christopher Rudolf will speak on optimising rare disease clinical trials with Real World Data at
